Wacker AG expands biotech business through €100m acquisition
Munich-based Wacker Group has purchased all shares of the Spanish CMO ADL BioPharma from financial investor Kartesia for €100m.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2082 entries already.
Entries by Thomas Gabrielczyk
BioBLU® Single-Use Bioreactors – Single-Use Simplicity
Single-use bioreactor technology offers a set of benefits compared to common glass or stainless-steel vessels, including reduced downtime between runs, minimal cleaning effort, or decreased cross-contamination risk. Advantages like these have generated an ever-growing demand for this technology over the years. In that regard, BioBLU® Single-Use Bioreactors combine the benefits of single-use bioreactor technology with the reliable performance of conventional glass or stainless-steel bioreactors.
Neogap Therapeutics AB partners with Cellerys AG
Swedish AI specialist Neogap Therapeutics AB will secect antigens for Cellerys AG, which wants to establish immune tolerance in a Phase II MS trial.
Conflict of interest?
In 2016, PharmaMar filed a European marketing authorisation application for Aplidin as a treatment for patients with multiple myeloma. After the European Medicines Agency rejected the MAA twice, which was accepted in Australia with the same data, PharmaMar sued the EC. European Biotechnology spoke with PharmaMar’s Chairman José María Fernández Sousa-Faro.
Dutch State to sell share capital of Intravacc BV
The State of the Netherlands, and the Dutch Ministry of Health, Welfare and Sport will sell all shares of vaccine maker Intravacc B.V.
Tay Therapeutics in licensing deal with VYNE Therapeutics
Tay Therapeutics Ltd announces licencing of its oral BET blocker TayB2 to VYNE Therapeutics Inc as a treatment for immuno-inflammatory and fibrotic disorders.
Medigene licences CD40L-CD28 costimulatory switch receptor
German Medigene AG has acquired global rights to the CD40L-CD28 costimulatory switch receptor that modulates the tumour stroma in order to make T-TCR therapies more effective.
EU to decarbonise aviation sector through green fuel targets
The European Commission has proposed to set binding sustainable aviation fuels (SAF) targets for the aviation sector to incentivise demand for and supply of SAF vs. kerosene.
Swiss Biotech Report: Sunrise, not sunset, is the feeling of the hour
In 2022, the Swiss biotech industry "continued to demonstrate its resilience, adapting well to geopolitical upheavals and remaining a key driver of innovation for global healthcare". Swiss biotech companies generated revenues of CHF 6.8bn. Capital inflows amounted to more than CHF 1.3bn, of which CHF 780m went to listed companies and CHF 550m to private companies. These are some of the findings of the annual industry report published by the Swiss Biotech Association in collaboration with EY and presented at Swiss Biotech Day in Basel.
Novartis in US$465m deal with 3B Pharmaceuticals GmbH
Targeted radiopharmaceuticals maker 3B Pharmaceuticals snaps US$40m upfront in a global exclusive licensing agreement for its FAP-Targeting Peptide Technology.